Incyte Corporation

Valuation Analysis

About the Company

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for

Incyte Corporation Stock at a Glance

Incyte Corporation (INCY) is currently trading at $108.53 with a market capitalization of $21.7B. The trailing P/E ratio stands at 15.33x, with a forward P/E of 11.84x. The 52-week range spans from $66.74 to $112.29; the current price is 3.3% below the yearly high. Year-over-year revenue growth stands at +20.9%. The net profit margin stands at 26.71%.

💰 Dividend

Incyte Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

23 analysts rate Incyte Corporation (INCY) on consensus: Buy. The average price target is $109.09, implying +0.51% from the current price. Analyst price targets range from $71.00 to $140.00.

Incyte Corporation: The Investment Case in Detail

Incyte Corporation (INCY) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 20.9% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 83.8% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 52.77% gross margin and 25.55% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat.

Valuation in Context

With a PEG ratio of 0.36, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 11.84x is meaningfully below the trailing 15.33x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 91.7% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (9.83%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Incyte Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.